Uncategorized

Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer

Published

on

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version